Opko Health Inc (NYSE:OPK) : The highest short term price target forecast on Opko Health Inc (NYSE:OPK) is $20 and the lowest target price is $10. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $15.25 with a standard deviation of $4.27.
Opko Health, Inc. has lost 4.21% in the last five trading days and dropped 11.3% in the last 4 weeks. Opko Health, Inc. has dropped 10.28% during the last 3-month period . Year-to-Date the stock performance stands at -7.06%.
Opko Health Inc (NYSE:OPK) : Zacks Investment Research ranks Opko Health Inc (NYSE:OPK) as 4, which is a Sell recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 1.8, which indicates as a Buy.
Opko Health Inc (NYSE:OPK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.12 and $9.08 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.46. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.34, notching a gain of 0.43% for the day. The total traded volume was 3,613,448 . The stock had closed at $9.30 on the previous day.
In an insider trading activity, Frost Gamma Investments Trust, CEO of Opko Health, Inc., had purchased 18,000 shares on June 22, 2016. The total value of the transaction was $171,180. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.